These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25046485)

  • 1. Potential novel role of bevacizumab in glioblastoma and cervical cancer.
    Goey AK; Figg WD
    Cancer Biol Ther; 2014 Oct; 15(10):1296-8. PubMed ID: 25046485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
    Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
    J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
    N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
    Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
    J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Dignam JJ; Armstrong TS; Wefel JS; Blumenthal DT; Vogelbaum MA; Colman H; Chakravarti A; Pugh S; Won M; Jeraj R; Brown PD; Jaeckle KA; Schiff D; Stieber VW; Brachman DG; Werner-Wasik M; Tremont-Lukats IW; Sulman EP; Aldape KD; Curran WJ; Mehta MP
    N Engl J Med; 2014 Feb; 370(8):699-708. PubMed ID: 24552317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
    Saran F; Chinot OL; Henriksson R; Mason W; Wick W; Cloughesy T; Dhar S; Pozzi E; Garcia J; Nishikawa R
    Neuro Oncol; 2016 Jul; 18(7):991-1001. PubMed ID: 26809751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASCO 2013: bevacizumab and glioblastoma--a marriage dissolution?
    Addeo R; Perri F; Parlato C; Della Vittoria G
    Curr Med Res Opin; 2014 Sep; 30(9):1871-3. PubMed ID: 24803042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.
    Malkki H
    Nat Rev Neurol; 2014 Apr; 10(4):179. PubMed ID: 24638136
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in glioblastoma--still much to learn.
    Fine HA
    N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Cloughesy T
    N Engl J Med; 2014 May; 370(21):2049. PubMed ID: 24860870
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab for newly diagnosed glioblastoma.
    Haines IE; Gabor Miklos GL
    N Engl J Med; 2014 May; 370(21):2048. PubMed ID: 24849089
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
    Lou E; Peters KB; Sumrall AL; Desjardins A; Reardon DA; Lipp ES; Herndon JE; Coan A; Bailey L; Turner S; Friedman HS; Vredenburgh JJ
    Cancer Med; 2013 Apr; 2(2):185-95. PubMed ID: 23634286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
    Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
    J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current role of anti-angiogenic strategies for glioblastoma.
    Thomas AA; Omuro A
    Curr Treat Options Oncol; 2014 Dec; 15(4):551-66. PubMed ID: 25173555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
    J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
    Vredenburgh JJ; Desjardins A; Reardon DA; Peters KB; Herndon JE; Marcello J; Kirkpatrick JP; Sampson JH; Bailey L; Threatt S; Friedman AH; Bigner DD; Friedman HS
    Clin Cancer Res; 2011 Jun; 17(12):4119-24. PubMed ID: 21531816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab as secondline treatment of glioblastoma -  worth the effort?
    Rovere RK
    Klin Onkol; 2014; 27(3):219-20. PubMed ID: 24918282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.